ATE483462T1 - Verwendung der epothilons zur behandlung der krebs - Google Patents

Verwendung der epothilons zur behandlung der krebs

Info

Publication number
ATE483462T1
ATE483462T1 AT99910257T AT99910257T ATE483462T1 AT E483462 T1 ATE483462 T1 AT E483462T1 AT 99910257 T AT99910257 T AT 99910257T AT 99910257 T AT99910257 T AT 99910257T AT E483462 T1 ATE483462 T1 AT E483462T1
Authority
AT
Austria
Prior art keywords
epothilones
treat cancer
epothilone
treatment
certain
Prior art date
Application number
AT99910257T
Other languages
German (de)
English (en)
Inventor
Terence O'reilly
Markus Wartmann
Manuel Litchman
Pamela Cohen
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Priority claimed from PCT/EP1999/001147 external-priority patent/WO1999043320A1/en
Application granted granted Critical
Publication of ATE483462T1 publication Critical patent/ATE483462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT99910257T 1998-02-25 1999-02-23 Verwendung der epothilons zur behandlung der krebs ATE483462T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones
PCT/EP1999/001147 WO1999043320A1 (en) 1998-02-25 1999-02-23 Use of epothilones for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE483462T1 true ATE483462T1 (de) 2010-10-15

Family

ID=27451759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910257T ATE483462T1 (de) 1998-02-25 1999-02-23 Verwendung der epothilons zur behandlung der krebs

Country Status (4)

Country Link
US (1) US6302838B1 (pt-PT)
JP (1) JP2011173928A (pt-PT)
AT (1) ATE483462T1 (pt-PT)
DE (1) DE69942827D1 (pt-PT)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
RU2313345C2 (ru) * 2001-02-27 2007-12-27 Новартис Аг Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона
US7030147B2 (en) * 2001-03-19 2006-04-18 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
CA2471509A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
MXPA04010853A (es) * 2002-05-01 2005-02-14 Novartis Ag Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer.
WO2004103267A2 (en) * 2002-05-20 2004-12-02 Kosan Biosciences, Inc. Methods to administer epothilone d
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1506203B1 (en) 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU2003267751A1 (en) * 2002-10-15 2004-05-04 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
JP4939220B2 (ja) * 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
US20060205795A1 (en) * 2003-06-27 2006-09-14 David Parkinson Cancer treatment with epothilones
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
EP2258704A1 (en) * 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2010065893A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
BRPI1012246A2 (pt) * 2009-03-25 2016-03-29 Novartis Ag composição farmacêutica contendo um fármaco e sirna
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ES2178093T5 (es) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用

Also Published As

Publication number Publication date
US6302838B1 (en) 2001-10-16
DE69942827D1 (de) 2010-11-18
JP2011173928A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
ATE483462T1 (de) Verwendung der epothilons zur behandlung der krebs
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
DE60033658D1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
NO20034056L (no) Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
DE60231439D1 (de) Mitotische kinesinhemmer
BR0214787A (pt) Compósitos elastoméricos, combinações de elastÈmeros e métodos
EE200000077A (et) Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
EE200300397A (et) Epotilooni derivaadid refraktaarsete kasvajate raviks
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
HK1076812A1 (en) Cyanoguanidine prodrugs
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
DE60106947D1 (de) Oxindolderivate
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
DE60143023D1 (de) Tumorhemmende nitroacridin-zusammensetzungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056453

Country of ref document: EP